Keyword: CRISPR Therapeutics
Pooling their technologies, Editas will work on cancer treatments and BlueRock will focus on neurology, cardiology and immunology.
After a year's delay, Editas Medicine will start enrolling patients in a phase 1/2 trial of its CRISPR-based treatment for LCA10, a rare form of blindness.
The FDA lifted a clinical hold it placed on Vertex and CRISPR Therapeutics’ gene-edited stem cell therapy for sickle cell disease.
CRISPR Therapeutics is partnering with ViaCyte to develop off-the-shelf, gene-edited stem cell therapies for diabetes in a deal worth up to $25 million.
In a blow to the University of California, a federal appeals court upheld CRISPR patents held by the Broad Institute.
Inscripta aims to broaden access to CRISPR by offering new enzymes for free, and to boost R&D by outfitting scientists with a full suite of tools.
ProQR Therapeutics reported interim phase 1/2 data for its LCA10 treatment showing it improved vision for the majority of patients.
CRISPR Therapeutics and Vertex Pharmaceuticals will test their gene therapy in patients with beta thalassemia.
Editas Medicine is to lose its chief medical officer at the end of the year, as the search is on for a new clinical leader.
Another study warns of potential toxicity with CRISPR gene-editing, and gives investors in biotechs developing the technology the jitters.